This publication has been commissioned and funded by MSD. The content is based on published studies and the author’s opinions and may not reflect the views of MSD. Please consult the full Data Sheets for any medications mentioned in this article at www.medsafe.govt.nz before prescribing. Treatment decisions based on these data are the full responsibility of the prescribing physician. This review is a concise summary of the important pharmacological and clinical characteristics of pembrolizumab (Keytruda®) for the treatment of non-small cell lung cancer (NSCLC). From 1st April 2023 Keytruda® has been funded for unresectable, advanced or metastatic NSCLC - eligibility criteria applies. Expert commentary on the use of pembrolizumab from a clinical practice perspective is provided by Dr Tony Rahman.
Please login below to download this issue (PDF)